Summary Slide.png (65.35 kB)

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial

figure

posted on 2020-04-16, 09:40 authored by Marc Evans, Robert G.J. Moes, Katrine Skipper Pedersen, Jens Gundgaard, Thomas R. Pieber

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s12325-020-01332-y

Usage metrics

Read the peer-reviewed publication

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial

Advances in Therapy

Keywords

Diabetes Health technology assessment Hypoglycaemia Insulin analogue Insulin therapy Pharmaco-economics

Licence

CC BY-NC 4.0

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports